The Nutraceutical Manufacturing Process: A Step-by-Step Guide for Formulators

Like pharmaceuticals, nutraceutical manufacturing is a controlled, multi-stage process that turns active ingredients into safe and consistent finished products. From formulation and raw material testing to production and packaging, each step affects product performance, stability, safety and compliance

As more nutraceutical brands outsource production, manufacturing quality is becoming a key differentiator. One market estimates nutraceutical contract manufacturing services at USD 174.09 billion in 2024 and projected growth to USD 195.76 billion in 2025, reflecting demand for scalable, compliant and technically capable partners (source).

Although nutraceuticals are often positioned closer to foods than medicines, their manufacture must still meet rigorous expectations for documentation, testing and quality control. This guide outlines the main stages of the process and highlights what formulators, quality teams and manufacturers need to consider when moving from development to commercial production.

Key Takeaways

• Nutraceutical manufacturing is a controlled, multi-stage process where raw material quality, formulation design, production controls, packaging and final testing all influence product performance and compliance.
• Ingredient identity, purity, potency and contaminant testing are essential controls, especially for botanicals, probiotics, vitamins and other sensitive or variable dietary ingredients.
• Formulation and scale-up decisions should be made early, as excipient choice, blend uniformity, compressibility, coating parameters and process validation can affect manufacturability at commercial scale.
• Film coating and packaging are part of the stability strategy, helping protect sensitive actives from moisture, oxygen, light, gastric acid or poor consumer experience.
• Working with experienced excipient, coating and packaging partners can help reduce reformulation risk, improve process robustness and support a smoother path from concept to finished product.

What Does Nutraceutical Manufacturing Involve?

Nutraceutical manufacturing covers the full journey from qualified raw materials to a finished product that is packaged, tested and ready for release. The process typically begins with supplier qualification and ingredient testing, followed by formulation development, stability testing, pilot-scale trials, scale-up, primary manufacturing, coating where required, packaging, quality control and final batch release.

The exact route depends on the dosage form. Tablets may require blending, granulation, compression and film coating. Capsules depend on powder flow, fill-weight control and shell compatibility. Softgels require careful control of fill material, shell formation and drying. Powders rely on blend uniformity, particle size control, flow properties and moisture management. In each case, the goal is the same: to make a product that can be manufactured consistently at scale and still meet its defined quality attributes.

• Master manufacturing records and batch production records provide the structure for this consistency. The master manufacturing record defines the formulation, equipment, process steps, specifications, packaging and labeling instructions for each product and batch size. The batch production record then captures what happened during a specific batch, including materials used, processing conditions, in-process checks, yields, deviations and quality approvals.
• A simple process flow diagram can help readers follow the sequence: raw material sourcing and testing → formulation development → scale-up → blending or granulation → compression, encapsulation, softgel production or powder blending → coating, where required → packaging and labeling → quality control review → product release.

Step 1: Raw Material Sourcing and Ingredient Testing

Raw material quality is a critical control in nutraceutical manufacturing. Every ingredient should come from an approved supplier and be supported by clear specifications, documentation and testing. Supplier qualification may include questionnaires, quality agreements, audit history, site information, change-control expectations and ongoing performance review.

A supplier CoA is useful, but it should not replace appropriate incoming testing. Under dietary supplement current Good Manufacturing Practice (cGMP) requirements, manufacturers must verify the identity of each dietary ingredient before use. Supplier CoAs may only be relied on when the supplier is qualified, the methods and results are documented and qualification is periodically reconfirmed.

Testing should reflect the ingredient type, risk profile and finished product specification. Common methods include HPLC for active content, ICP-MS for heavy metals, PCR or DNA-based methods for botanical identity and microbial testing for bioburden. Additional testing may be needed for pesticides, residual solvents, allergens, adulterants or mycotoxins.

Botanical and herbal ingredients need particular attention because natural variation, harvest conditions and processing can affect composition. Confirming plant species, monitoring for adulteration and standardizing active or marker compounds help reduce variability and support label accuracy.

If a formulation includes a New Dietary Ingredient, the regulatory pathway should be assessed early. In the United States, an NDI notification may be required before marketing, so early review can help prevent delays later in development.

Step 2: Formulation Development

This stage begins with active ingredient selection and dose determination, balancing the intended benefit, regulatory limits, label claims, consumer expectations and the practical constraints of the chosen format. Excipient selection is important. Fillers, binders, disintegrants, lubricants, glidants and coating systems all influence how a supplement behaves during manufacturing and how it performs for the consumer. The right excipient system can improve powder flow, compressibility, tablet strength, disintegration, stability, taste masking and overall product appearance.

Compatibility studies help identify whether actives and excipients remain physically and chemically stable when combined. This is especially important for complex nutraceutical formulations that include vitamins, minerals, botanicals, probiotics or lipid-based actives, where interactions can affect potency, color, odor, dissolution, moisture uptake or shelf life.

Prototype batches are then developed and tested iteratively. Each trial should assess whether the formulation can be blended, granulated, compressed, encapsulated or coated consistently, while meeting target quality attributes such as assay, uniformity, disintegration, dissolution and physical stability.

Accelerated stability testing can provide an early indication of how the formulation may perform under elevated temperature and humidity. These studies help guide decisions on ingredient levels, protective coatings, packaging requirements and storage conditions before the product moves into scale-up.

Clean-label expectations may add further constraints. Formulators often need to avoid certain colors, synthetic additives, animal-derived ingredients or allergens while still achieving manufacturability, stability and an acceptable consumer experience. Addressing these requirements early reduces reformulation risk later in development.

Step 3: Scale-Up and Process Validation

Scale-up is the point where a formulation must prove it can move from lab bench to pilot and commercial production without losing quality or consistency. A process that works well in small development batches may behave differently at larger volumes, where mixing efficiency, heat transfer, equipment geometry, residence time and material handling can all change.

Pilot batches help identify these risks before full commercial manufacture. They are used to confirm practical batch sizes, refine process parameters, test in-process controls and determine whether the formulation can meet target quality attributes repeatedly. At this stage, manufacturers may need to adjust blending time, granulation conditions, compression settings or coating parameters to maintain performance at scale.

Equipment qualification supports this transition. Installation Qualification (IQ) confirms that equipment has been installed correctly; Operational Qualification (OQ) verifies that it functions as intended across defined operating ranges; and Performance Qualification (PQ) demonstrates that the equipment performs consistently under routine production conditions. Together, IQ, OQ and PQ provide documented evidence that the process is ready for controlled manufacturing.

Process validation should also be reflected in the master manufacturing record. This documentation defines the approved formulation, equipment, processing steps, critical parameters, in-process checks, sampling plans, acceptance criteria and packaging instructions. Once validated, any change to the process, equipment or material source should be reviewed through change control to confirm that product quality remains protected.

Common scale-up failure points include blend segregation, granule size variability, changes in powder flow, inconsistent tablet hardness, longer drying times and altered coating dynamics in larger pans. Addressing these issues early helps reduce rework, avoid batch failures and support a smoother transfer into commercial production.

Step 4: Blending and Granulation

Blending and granulation prepare the formulation for consistent downstream processing. The aim is to create a uniform mixture of actives and excipients with the right flow, density and particle size profile for compression, encapsulation or further processing.

Dry blending is often considered the simplest route, especially when materials have good flow and similar particle size or density. It avoids added moisture and heat, making it useful for sensitive ingredients such as probiotics, enzymes, certain botanicals and some vitamins. However, the process must be carefully controlled to prevent segregation, over-mixing or poor content uniformity.

Wet granulation uses a liquid binder to agglomerate fine powders into larger granules. This can improve flow, reduce dust, support uniform active distribution and improve compressibility. It is often selected when powders are cohesive, poorly flowing or difficult to compress, but it may not be suitable for moisture- or heat-sensitive actives because the granules must be dried before further processing.

Dry granulation, including roller compaction, improves flow and compressibility without using a liquid binder. The powder blend is compacted into ribbons or slugs, milled into granules and blended again before compression or filling. This route is useful for moisture-sensitive materials, but compaction force, ribbon density and milling conditions must be controlled to avoid excessive fines or poor tablet strength.

Critical quality attributes at this stage include blend uniformity, particle size distribution, bulk and tapped density, flow properties, moisture content and granule strength. Monitoring these attributes helps ensure the blend feeds consistently into the next process step and supports reliable tablet weight, capsule fill weight, disintegration and finished product performance.

Step 5: Tablet Compression and Capsule Filling

Once the blend or granules are ready, the formulation is converted into the final dosage form through tablet compression, hard-shell capsule filling or softgel encapsulation. The selected route depends on ingredient properties, dose size, stability, consumer preference and the level of protection needed for the active ingredients.

For tablets, formulators must decide whether the blend can be directly compressed or whether granulation is needed first. Direct compression is typically preferred when the blend has suitable flow, compressibility and content uniformity. Granulation may be required when powders are cohesive, poorly flowing, low dose, moisture sensitive or prone to segregation.

Compression parameters must be carefully controlled because small changes can affect tablet quality. Compression force, tooling design, feeder speed and turret speed all influence tablet weight, hardness, thickness, friability and disintegration. Too little force can lead to weak tablets, while excessive force may slow disintegration, increase sticking or contribute to capping and lamination.

For hard-shell capsules, consistent powder flow and fill weight control are critical. Tamping pin systems compact powder into a plug using repeated compression steps, while dosator systems collect and eject a measured powder slug from a powder bed. The best option depends on powder density, flow behaviour, dose size and the required fill-weight accuracy.

Softgels are produced through a rotary die process that forms, fills and seals the capsule in one continuous operation. They are often used for oils, lipid-based actives and liquid or semi-solid fills. Fill viscosity, shell composition, moisture content and drying conditions must all be controlled to support capsule integrity and stability.

In-process quality checks help confirm that the dosage form remains within specification throughout production. Typical checkpoints include tablet or capsule weight variation, tablet hardness, thickness, friability, disintegration and visual appearance. These checks allow operators to adjust process settings before small variations become full batch failures.

Excipient choice can make this stage easier to control. Excipients such as Nutracore and Starch 1500^® can help improve flow, compressibility and disintegration, supporting simpler manufacturing routes for suitable nutraceutical formulations.

Step 6: Film Coating

Film coating is one of the most important finishing steps in nutraceutical tablet manufacturing. Beyond improving appearance, a well-designed coating can protect sensitive ingredients from moisture, light and oxygen, mask unpleasant taste or odor, improve swallowability and help differentiate a brand on shelf.

The right coating depends on the formulation and the product claim. Immediate-release film coats are commonly used to improve tablet finish, color consistency and consumer appeal. Moisture-barrier coatings help protect hygroscopic actives such as minerals, B-vitamins, botanicals and probiotics. Enteric coatings are used when ingredients need protection from gastric acid or when release is intended in the small intestine. Modified-release coatings may also be considered where a controlled or delayed release profile is required.

Coating performance depends on both formulation and process control. Pan speed, spray rate, inlet air temperature and humidity, atomization pressure, airflow and pan load all influence how evenly the coating is applied and dried. If the spray rate is too high or drying is insufficient, tablets may over wet, stick or pick. If drying is too aggressive, the film may become rough, brittle or uneven.

Coating weight gain and coating weight uniformity are critical quality attributes. Too little coating may leave the core exposed, reducing moisture protection, taste masking or acid resistance. Too much coating can affect tablet size, appearance, process time and, in functional applications, dissolution performance. Regular in-process weight checks help confirm that the target coating level is being reached consistently across the batch.

Enteric coating requires particular care because performance is functional, not just cosmetic. The coating must remain intact in acidic gastric conditions and then allow release at the appropriate intestinal pH. This makes core robustness, coating level, film continuity and dissolution testing especially important. For ingredients such as probiotics, enzymes, fish oil or odor-sensitive actives, enteric coating can also support consumer experience by reducing unpleasant aftertaste, reflux or gastric irritation.

Clean label expectations add another layer of complexity. Nutraceutical brands may need coatings that avoid titanium dioxide, talc, synthetic colors, animal-derived ingredients or allergens, while still delivering opacity, color consistency, process efficiency and stability. This is where fully formulated coating systems can simplify development by combining polymers, plasticizers, pigments and other functional ingredients in a system designed for nutritional and dietary supplement applications.

Common film coating defects include picking, sticking, twinning, roughness, logo bridging, color variation, cracking and mottling. These issues often point to a mismatch between the tablet core, coating formulation and process conditions. Root causes may include a weak or friable core, high spray rate, low product temperature, poor atomization, incorrect pan loading, inadequate drying or insufficient suspension mixing.

Colorcon's nutraceutical coating portfolio supports these different needs through solutions such as Nutrafinish^®  film coating systems for appearance, label-friendly positioning, moisture protection and swallowability, and Nutrateric for enteric applications. Selecting the right coating early in development helps formulators reduce reformulation risk, improve process robustness and protect product quality through shelf life.

Step 7: Packaging and Labeling

Packaging is part of the product stability strategy, not just the final presentation. The right format should protect the supplement from moisture, oxygen, light, contamination and physical damage while also supporting usability, brand identity and regulatory compliance.

Primary packaging options include bottles, blisters, sachets, pouches, and tubes. Selection depends on the dosage form, ingredient sensitivity, target shelf life, pack size, consumer use pattern and distribution conditions. Tablets and capsules are often packed in bottles or blisters, powders may require sachets or high-barrier pouches, and effervescent tablets typically need moisture-protective tubes or closures.

Barrier requirements should be matched to the active ingredients. Probiotics, enzymes, effervescent tablets, minerals and botanical extracts may need strong moisture protection. Fish oil, CoQ10 and some vitamins are more sensitive to oxygen and light. Desiccants, oxygen absorbers, induction seals, high-barrier films, amber or opaque containers and controlled atmosphere packaging can all help create a more protective microenvironment around the product.

Labeling must also be reviewed before release to confirm it meets the requirements of each target market. While specific rules vary by country or region, labels typically need to include a clear product identity, quantity, ingredients or nutrition information, directions for use where appropriate, manufacturer or distributor details, batch or lot information, expiry or best-before date, required warnings and any substantiated claims. Claims should be reviewed carefully to ensure they are accurate, compliant and supported by appropriate evidence.

Batch coding, serialization and packaging component reconciliation support traceability throughout distribution. Each finished pack should be linked back to the batch record, raw material lots, packaging components and label version used. This helps manufacturers manage complaints, returns, stability investigations or recalls quickly and accurately.

Step 8: Quality Control, Testing, and Batch Release

Quality control confirms that the finished product meets its approved specifications before it is released. Testing should verify the product’s identity, strength, composition, purity and safety, as well as any performance attributes linked to the dosage form or product claim.

Finished product testing may include active content against label claim, dissolution or disintegration, microbial limits, heavy metals, moisture content, residual solvents, allergens, pesticides or other contaminants where relevant. Analytical methods should be suitable for the ingredient and product matrix, with common techniques including HPLC, ICP-MS, GC, PCR or DNA-based testing and microbial enumeration.

The batch production record is reviewed alongside test results before release. This review should confirm that the correct materials, equipment, process parameters, packaging components and labels were used; that in-process checks were completed; that yields were within expected ranges; and that any deviations were investigated and approved by the quality unit.

Out-of-specification results and deviations must be handled through a documented investigation. The manufacturer should assess whether the issue is due to laboratory error, process variation, material quality, equipment performance or packaging failure, then define corrective and preventive actions before deciding whether the batch can be released, reworked, rejected or held for further evaluation.

Some brands also use voluntary third-party certification programs to strengthen quality assurance and consumer trust. Certifications such as NSF/ANSI 173, USP Verified or Informed Sport may involve facility audits, product testing, label review and ongoing surveillance. These programs do not replace cGMP compliance, but they can provide an additional layer of independent verification.

Regulatory Framework for Nutraceutical Manufacturing

Nutraceutical manufacturing in the USA is regulated primarily as food manufacturing, not pharmaceutical manufacturing. However, the FDA's cGMP requirements for dietary supplements are significantly more demanding than conventional food GMPs in several areas.

*Verify before publishing (based on SERP research)

Own-site vs. Contract Nutraceutical Manufacturing

The decision to manufacture nutraceuticals own-site or work with a contract manufacturer depends on business strategy, technical capability, capital investment and speed-to-market requirements. Both approaches can support high-quality products when supported by strong formulation, process control and quality systems.

Own-site manufacturing can make sense for companies with large production volumes, established demand and the resources to invest in equipment, people, quality systems and regulatory oversight. It may also be preferred when the process is highly proprietary, when intellectual property needs close protection, or when vertical integration gives the brand greater control over supply, cost and product quality.

Contract manufacturing (CMO or CDMO) is often preferred by start-up brands, companies with limited capital investment, or businesses that need specialist dosage form expertise. A CMO or CDMO can provide established manufacturing infrastructure, trained operators, analytical capabilities, quality systems and regulatory support. This can help brands launch faster, scale more flexibly and focus internal resources on product strategy, marketing and distribution.

The contract manufacturing market is growing as nutraceutical brands look for scalable, compliant and technically capable partners. One market estimate values global nutraceutical contract manufacturing services at USD 194.89 billion in 2025, with projected growth to USD 218.34 billion in 2026 (source). This growth reflects the increasing complexity of supplement development, including clean-label expectations, specialized dosage forms, regulatory requirements and the need for robust quality control.

Excipient and coating suppliers can support both models. For own-site manufacturers, they can help strengthen formulation design, process efficiency and scale-up robustness. For CMOs and CDMOs, they can provide ready-to-use excipient and coating systems, technical troubleshooting, regulatory documentation and application expertise across multiple customer projects. In both cases, early supplier involvement can reduce development risk and help teams move more confidently from concept to commercial manufacture.

Common Manufacturing Challenges

How Colorcon Supports the Nutraceutical Manufacturing Process

Manufacturing a successful nutraceutical product requires more than choosing the right active ingredients. Formulators also need excipients, coatings and technical support that help the product move smoothly from development to commercial production. Colorcon supports nutraceutical brands and manufacturers across this process, from core formulation and dosage form development to coating selection, scale-up and troubleshooting.

For tablet and capsule development, Colorcon offers excipient systems that can make formulation easier and improve manufacturing performance. Nutracore label-friendly fillers and lubricants can help support clean-label goals while improving powder flow, compression and processing. StarTab^® can support direct compression when a simpler tablet manufacturing route is possible, while StarCap^® can help improve capsule filling for suitable powder blends. HPMC polymers can help strengthen tablet cores and support controlled-release performance where needed.

Colorcon’s nutraceutical film coating portfolio also helps address common finishing and stability challenges. Nutrafinish coating systems are designed for nutritional and dietary supplement products, with options for label-friendly positioning, moisture protection, titanium dioxide-free formulations, high-performance coating and easier swallowability. Nutrateric supports enteric applications where ingredients need protection from gastric acid or targeted release in the small intestine.

These systems can help reduce development complexity by providing ready-to-use technologies backed by formulation and application expertise. Instead of developing every excipient or coating approach from scratch, manufacturers can work with Colorcon to select solutions that fit the active ingredient, dosage form, label goals, process conditions and target market requirements.

Colorcon’s technical teams can also support formulation development, process scale-up, coating process optimization, analytical testing guidance and regulatory documentation. This support is especially valuable for complex nutraceuticals, including products with moisture-sensitive actives, challenging powders, large tablets, clean-label requirements or enteric coating needs.

Whether manufacturing in-house or working with a CMO/CDMO, involving Colorcon early can help reduce reformulation risk, improve process robustness and support a more efficient path from concept to finished product. Formulators can contact Colorcon’s technical team to discuss a specific challenge, review coating or excipient options, or request a sample for evaluation.

Related Resources

• Types of Nutraceuticals: Categories, Examples and Dosage Forms
• Is a Nutraceutical the Same Thing as a Dietary Supplement? 
• Nutraceutical Trends
  
• The Challenges & Opportunities of Complex Nutraceutical Products

Frequently Asked Questions

• What is nutraceutical manufacturing?

  Nutraceutical manufacturing is the controlled process of turning dietary ingredients, such as vitamins, minerals, botanicals, probiotics or other bioactives, into finished supplement products. It includes formulation, raw material testing, blending, granulation, compression or encapsulation, coating, packaging and quality control.

• What are the key steps in the nutraceutical manufacturing process?
  
  

  The key steps in the nutraceutical manufacturing process are raw material sourcing and testing, formulation development, scale-up, blending or granulation, tablet compression or capsule filling, film coating where required, packaging and labeling, quality control testing and final batch release.

• What GMP regulations apply to nutraceutical manufacturing?

   

  In the United States, dietary supplement manufacturing is primarily regulated under 21 CFR Part 111, which sets cGMP requirements for manufacturing, packaging, labeling and holding dietary supplements. These requirements cover identity testing, specifications, master manufacturing records, batch records and quality control review.

• What is the difference between nutraceutical manufacturing and pharmaceutical manufacturing?

   

  Nutraceuticals are usually regulated as foods or dietary supplements, while pharmaceuticals are regulated as medicines. Pharmaceutical manufacturing typically requires drug approval and follows drug cGMP requirements, while nutraceutical manufacturing focuses on supplement quality, safety, label accuracy and compliance with dietary supplement regulations.

• What role does film coating play in nutraceutical manufacturing?

   

  Film coating can improve the appearance, swallowability, taste masking and stability of nutraceutical tablets. Functional coatings may also provide moisture protection, light protection or enteric release for ingredients that need protection from stomach acid or targeted release in the intestine.

• Should I manufacture nutraceuticals in-house or use a contract manufacturer?

  
  

  In-house manufacturing may be best for companies with high volumes, strong technical resources and a need for close control. Contract manufacturing may be better for brands that need specialist equipment, formulation expertise, faster scale-up or lower capital investment. The best choice depends on volume, dosage form, quality requirements, budget and launch timeline.